articleThe Lancet OncologyJun 5, 2015Closed access

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

National Taiwan University Hospital · Massachusetts General Hospital · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.

Funding